Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD1 | P21728 | 2/20 | 0.53 |
| ▸ | F3 | P13726 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allocryptopine SCHEMBL29568468 | 1.00 | CYP2D6 (1.00) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| Allocryptopine SCHEMBL30477770 | 1.00 | CYP2D6 (1.00) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL3368057 | 0.89 | CYP2D6 (0.80) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL11891038 | 0.87 | CYP2D6 (0.77) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL31501083 | 0.87 | CYP2D6 (0.77) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL3271155 | 0.87 | CYP2D6 (0.77) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL11817332 | 0.85 | CYP2D6 (0.73) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL16970984 | 0.83 | CYP2D6 (0.84) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| Allocryptopine SCHEMBL10384490 | 0.82 | CYP2D6 (0.67) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E | |
| SCHEMBL178013 | 0.82 | CYP2D6 (1.00) | CYP2D6KMT2ACYP2C19CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-12485112-B2 | Pharmaceutical composition | ASCLEPIUS PHARMACEUTICAL LLC (US) | 2025-12-02 | — | — | US | claimed |
| CN-119432631-A | Recombinant bacterium and application thereof in production of benzophenanthridine alkaloids | 陈云 | 2025-02-14 | — | — | CN | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| CN-118806779-A | Pharmaceutical composition and preparation method and application thereof | 陕西盘龙药业集团股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118518778-A | Detection method and screening method for quality markers of artemisia rupestris | 西南民族大学 | 2024-08-20 | — | — | CN | claimed |
| US-20240148705-A1 | PHARMACEUTICAL COMPOSITION | ASCLEPIUS PHARMACEUTICAL LLC (US) | 2024-05-09 | — | — | US | claimed |
| US-11865107-B2 | Pharmaceutical composition | ASCLEPIUS PHARMACEUTICAL LLC (US) | 2024-01-09 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| JP-2006516633-A | — | — | 2006-07-06 | — | — | JP | claimed |
| WO-2006032380-A1 | QUATERNARY ALKALOID DERIVATIVES OF CHELIDONIUM MAJUS L | NOWICKY WASSILI (AT) | 2006-03-30 | — | — | WO | claimed |
| CN-1747726-A | A therapeutic composition for the treatment of hiv-1 and hiv-2 | EXCYTON EXCYMER GMBH (CH) | 2006-03-15 | — | — | CN | claimed |
| EP-1589961-A4 | A THERAPEUTIC COMPOSITION FOR THE TREATMENT OF HIV-1 AND HIV-2 | EXCYTON EXCYMER GMBH (CH) | 2006-02-15 | — | — | EP | claimed |
| EP-1589961-A2 | A THERAPEUTIC COMPOSITION FOR THE TREATMENT OF HIV-1 AND HIV-2 | Excyton-Excymer GmbH (CH) | 2005-11-02 | — | — | EP | claimed |
| CN-1218948-C | Process for separating and preparing hig purity samguinarine and chelerythrine | UNIV HUNAN NORMAL (CN) | 2005-09-14 | — | — | CN | claimed |
| CN-1532198-A | Quaternary chelidonine derivatives | ά����ŵά�Ļ� | 2004-09-29 | — | — | CN | claimed |
| CN-1532197-A | Process for separating and preparing hig purity samguinarine and chelerythrine | 湖南师范大学 | 2004-09-29 | — | — | CN | claimed |
| WO-2004066954-A2 | A THERAPEUTIC COMPOSITION FOR THE TREATMENT OF HIV-1 AND HIV-2 | EXCYTON-EXCYMER GMBH (CH) | 2004-08-12 | — | — | WO | claimed |
| CN-1422859-A | reaction method of alkaloid, reaction product and application thereof | HUATZ NORVICH (AT) | 2003-06-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485112-B2 | Pharmaceutical composition | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADRA2C, CPT1A | CYP2D6 111/4885KMT2A 2630/4885CYP2C19 250/4885 |
| US-20240148705-A1 | PHARMACEUTICAL COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADRA2C, CPT1A | CYP2D6 111/4885KMT2A 2630/4885CYP2C19 250/4885 |
| US-11865107-B2 | Pharmaceutical composition | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADRA2C, CPT1A | CYP2D6 111/4885KMT2A 2630/4885CYP2C19 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.